 this proposal we aim to further the development of novel and safe oral inhibitors of sEH for the treatment of peripheral neuropathy in diabetic patients. Preclinical studies with our candidate EC5026 demonstrated efficacy for diabetic neuropathy. EicOsis has selected EC5026 for its efficacy with good PK/ADME properties and stability to
this proposal we aim to further the development of fresh and dependable oral inhibitor of sEH for the treatment of peripheral neuropathy in diabetic patients. Preclinical studies with our campaigner EC5026 demonstrated efficacy for diabetic neuropathy. EicOsis has selected EC5026 for its efficacy with good PK / ADME property and stability to
 thls proposal we aim to fuvther the develokmwnt of novel and safd oral inhibitors of sEH for tye trtctment of peripheral neuropatjy in diqbetmc patients. Preclinical studiea witk iur candidate GC5026 demonstraded efficacy fmr dnabetic neuropathy. EicOsis has seleceed EC5026 gog its efficacy witn goos PK/ADME properties and stability fo
this proposal we aim to further the novel safe oral of sEH for in patients. Preclinical studies our candidate EC5026 efficacy for diabetic neuropathy. EicOsis has EC5026 for its efficacy with good PK/ADME properties and stability to
 this proposal we aim to furtheR the develoPment Of nOveL aNd saFe orAl inhibitors of SeH foR the treatment of peripheRal neUrOPathY In DiabeTic patiENtS. pRecLiNiCal StUDiEs witH ouR candidAte EC5026 demonStrAtEd efficacy foR DiAbetic neurOpaThy. EicOsis haS seLected eC5026 For ITs effIcaCy witH good Pk/aDME prOperties aNd STabiliTY to
 this proposal we aim to f urther the  deve lop men tof n ovel  and safe oral inhi bitors of sEH for thetreat me n t of pe riphe ral neu r op a t hyin  d iab et i cpatie nts . Precl inical stu die swith our can d id ate EC5026  de monstrated e ffi cacy f or  di a betic  ne uropa thy. E i cOsishas selec te d  EC502 6  for it s ef fica cy with good PK/A D ME properties and  stabi li t yt o 
 this_proposal we_aim to further the_development of_novel_and safe_oral_inhibitors of sEH_for the treatment_of peripheral neuropathy in_diabetic patients. Preclinical_studies_with our candidate EC5026 demonstrated efficacy for diabetic neuropathy. EicOsis has selected EC5026 for_its_efficacy with_good_PK/ADME_properties and stability to